Temazepam Shortage: What Providers and Prescribers Need to Know in 2026

While temazepam is not currently listed on the FDA's Drug Shortage Database, prescribers are increasingly fielding calls from patients unable to fill their Restoril or generic temazepam prescriptions. Understanding the structural causes of this availability friction — and having a clinical action plan ready — allows providers to manage these situations efficiently without disrupting patient care.

The Current Availability Landscape for Temazepam

As of 2026, temazepam is not in an FDA-declared national shortage. Multiple generic manufacturers — including Sandoz, Mylan, Amneal, and Novel Laboratories — continue to produce the drug in all four strengths (7.5 mg, 15 mg, 22.5 mg, and 30 mg). Brand-name Restoril remains available but at a steep premium.

The availability challenges providers are encountering are primarily localized and pharmacy-specific, driven by the structural characteristics of Schedule IV controlled substance dispensing rather than a true supply crisis. Understanding these dynamics helps providers set patient expectations accurately and respond proactively.

Key Drivers of Localized Temazepam Unavailability

DEA Schedule IV Purchasing Constraints

As a DEA Schedule IV substance, temazepam is subject to federal purchasing limits at the pharmacy level. Each pharmacy has a controlled substance ordering quota that resets on a periodic basis. When demand spikes unexpectedly — or when a pharmacy underestimates its needs — the pharmacy cannot simply order additional supply until the next ordering cycle. This creates temporary out-of-stock situations that can last days to a week or more.

Declining Prescribing Volume Creates Thin Margins

Prescriptions for benzodiazepine hypnotics like temazepam have declined substantially since 2010, as z-drugs (zolpidem, eszopiclone) and newer agents (orexin antagonists, melatonin agonists) have become first-line options. In 2021, temazepam was the 208th most prescribed medication in the U.S. with approximately 2 million prescriptions — a significant decrease from earlier decades. Pharmacies have adjusted their par levels downward accordingly, leaving less buffer stock for each patient.

Prescription Transfer Limitations

Unlike non-controlled prescriptions, Schedule IV prescriptions have transfer limitations that vary by state. In many states, only one transfer is permitted, and some states require that controlled substance prescriptions go directly from prescriber to dispensing pharmacy. This means that when a pharmacy is out of stock, the patient must contact your office for a new prescription routed to a pharmacy with available supply — creating a time and workflow burden.

Clinical Considerations When Temazepam Is Unavailable

Never Advise Abrupt Discontinuation

Benzodiazepine withdrawal can be clinically severe and potentially life-threatening. Patients on regular temazepam should never be advised to abruptly stop if their prescription cannot be filled. If a patient calls reporting they cannot find their medication and are running low, same-day clinical action is warranted: either locate a pharmacy with stock, provide a bridging prescription, or initiate a supervised taper protocol.

Bridging Alternatives to Consider

If temazepam genuinely cannot be located in your patient's area, the following substitutions may be clinically appropriate with proper oversight:

Diazepam (Valium): Longer-acting benzodiazepine; commonly used in taper protocols; Schedule IV; widely stocked.

Lorazepam (Ativan): Intermediate-acting benzodiazepine; may help prevent withdrawal for patients who cannot access temazepam temporarily; Schedule IV.

Zolpidem (Ambien): Not a benzodiazepine and not a withdrawal substitute, but may adequately address the insomnia indication if dependence is not yet established; most widely stocked hypnotic in the U.S.

Trazodone: Non-controlled; non-addictive; effective for insomnia; does not address withdrawal risk but maintains sleep treatment continuity.

Workflow Recommendations for Your Practice

To reduce the administrative burden of temazepam availability calls, consider implementing these practice-level strategies:

Ask patients to confirm pharmacy stock availability before their appointment, especially for refills. Instruct your front desk to include a reminder in appointment prep messages for patients on Schedule IV sleep medications.

Send prescriptions electronically directly to the dispensing pharmacy, not to a patient's phone for them to route. For controlled substances, e-prescribing directly to the identified pharmacy reduces ambiguity and transfer issues.

Recommend medfinder to your patients. medfinder.com/providers is a resource that helps patients proactively locate pharmacies with their medication in stock, reducing the inbound calls to your practice.

Document availability attempts. If a patient cannot fill a controlled substance prescription due to stock issues, document this in the clinical record with dates, pharmacies contacted, and actions taken. This protects your practice and supports patient safety continuity.

Telehealth Prescribing Update for 2026

As of 2026, DEA has continued to extend telehealth prescribing flexibilities for Schedule IV controlled substances, meaning providers can prescribe temazepam via telehealth without requiring an in-person visit. This remains subject to state law, so verify local requirements. The extended telehealth provisions apply through at least the end of 2026.

Supporting Your Patients with Resources

Directing patients to the right resources can reduce the burden on your clinical staff. Share our patient-facing shortage update with patients who have questions about supply, and consider registering your practice at medfinder.com/providers to learn how medfinder can help your patients locate their medications.